关于金宇生物技术股份有限公司 2023 年度向特定对象发行 A 股股票 并在主板上市 之 发行保荐书 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 发行保荐书 华泰联合证券有限责任公司 关于金宇生物技术股份有限公司 2023 年度向特定对象发行 A 股股票并在主板上市 之发行保荐书 金宇生物技术股份有限公司（以下简称"公司"、"发行人"、"生物股份"） 申请向特定对象发行 A 股股票并在主板上市，依据《公司法》《证券法》《上市 公司证券发行注册管理办法》（以下简称"《再融资注册办法》"）《上海证券交易 所上市公司证券发行上市审核规则》等相关法律、法规的有关规定，提交发行申 请文件。华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"） 作为其本次发行的保荐人，田栋和王骋道作为具体负责推荐的保荐代表人，特为 其出具本发行保荐书。 保荐人华泰联合证券、保荐代表人田栋和王骋道承诺：本保荐人和保荐代表 人根据《公司法》《证券法》等有关法律、法规和中国证监会、上海证券交易所 的有关规定，诚实守信、勤勉尽责，严格按照依法制定的业务规则、行业执业规 范和道德准则 ...

关于金宇生物技术股份有限公司 2023 年度向特定对象发行 A 股股票 并在主板上市 之 上市保荐书 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 上市保荐书 华泰联合证券有限责任公司 关于金宇生物技术股份有限公司 2023 年度向特定对象发行 A 股股票并在主板上市 之上市保荐书 上海证券交易所： 作为金宇生物技术股份有限公司（以下简称"公司"、"发行人"、"生物股份"） 向特定对象发行 A 股股票并在主板上市的保荐人，华泰联合证券有限责任公司 及其保荐代表人已根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）等法律法规和中国证券监督管理委员 会（以下简称中国证监会）及贵所的有关规定，诚实守信，勤勉尽责，严格按照 依法制定的业务规则和行业自律规范出具上市保荐书，并保证所出具文件真实、 准确、完整。 如无特别释义，本上市保荐书释义与《金宇生物技术股份有限公司 2023 年 度向特定对象发行 A 股股票并在主板上市募集说明书》一致。 3-2-1 上市保荐书 一、发行人基本情况 5、法定代表人：张翀宇 6、联系方 ...

北京市嘉源律师事务所 关于金宇生物技术股份有限公司 2023 年度向特定对象发行 A 股股票并在主板上市的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 二〇二三年八月 | 释 义 2 | | --- | | 一、本次发行的授权和批准 7 | | 二、本次发行的主体资格 12 | | 三、本次发行的实质条件 12 | | 四、发行人的股本及其演变 16 | | 五、发行人的控股股东及实际控制人 16 | | 六、发行人的独立性 16 | | 七、发行人的业务 16 | | 八、 关联交易及同业竞争 17 | | 九、 发行人的主要财产 18 | | 十、 发行人的重大债权债务 19 | | 十一、发行人重大资产变化及收购兼并 20 | | 十二、发行人公司章程的制定及修改 20 | | 十三、发行人股东大会、董事会、监事会议事规则及规范运作 20 | | 十四、发行人董事、监事和高级管理人员及其变化 21 | | 十五、发行人的税务及财政补贴 21 | | 十六、发行人的环境保护和产品质量、技术等标准 22 | | 十七、发行人募集资金的运用 22 | | 十八、发行人的业务发展目标 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2023-057 金宇生物技术股份有限公司 关于参加内蒙古辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，金宇生物技术股份有限公司（以下简 称"公司"）将参加由内蒙古证监局、内蒙古自治区上市公司协会与深圳市全 景网络有限公司联合举办的"2023 年内蒙古辖区上市公司投资者集体接待日活 动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与本次互动交流，活动时间为 2023 年 6 月 9 日（周五） 15:30-17:00。 届时公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 金宇生物技术股份有限公司 董 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2023-056 金宇生物技术股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 09 日(星期五) 下午 13:00-14:30 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 06 月 02 日(星期五) 至 06 月 08 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@jinyu.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 金宇生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日 披露公司《2022 年年度报告》和《2023 年第一季度报告》，为便于广大投资者 更全面深入地了 ...

Financial Performance - In 2022, the company achieved operating revenue of CNY 1,528,669,256.29, a decrease of 13.94% compared to CNY 1,776,317,811.37 in 2021[39]. - The net profit attributable to shareholders was CNY 210,676,539.06, down 44.89% from CNY 382,286,663.10 in the previous year[39]. - The net profit after deducting non-recurring gains and losses was CNY 196,152,187.97, a decline of 47.08% compared to CNY 370,633,265.99 in 2021[39]. - The net cash flow from operating activities was CNY 344,650,092.40, down 35.35% from CNY 533,084,549.84 in the previous year[39]. - The company's total assets at the end of 2022 were CNY 6,389,335,025.55, a decrease of 3.25% from CNY 6,603,925,651.78 at the end of 2021[39]. - The net assets attributable to shareholders decreased by 3.79% to CNY 5,072,201,306.08 from CNY 5,272,250,740.06 in 2021[39]. - Basic earnings per share decreased by 44.12% to ¥0.19 in 2022 from ¥0.34 in 2021[73]. - The weighted average return on equity decreased by 3.43 percentage points to 3.96% in 2022 from 7.39% in 2021[73]. Research and Development - The company’s R&D investment reached 203 million CNY, accounting for 13.30% of total revenue, with 134 million CNY in expense-based R&D (65.77%) and 70 million CNY in capitalized R&D (34.23%) in 2022[77]. - The company has established an integrated R&D platform for African swine fever vaccines, with significant breakthroughs in subunit and mRNA vaccine development, demonstrating strong safety and efficacy[77]. - The company is advancing the development of multi-valent vaccines, with several new vaccines entering clinical trial application stages in 2023[78]. - The company has optimized its distribution channels and enhanced its marketing team to improve market penetration and sales of non-foot-and-mouth disease products[79]. - The company is focusing on innovation-driven development in the biopharmaceutical industry, aligning with national strategies for agricultural modernization[82]. - The company is committed to improving its market insight and enhancing its technical service capabilities to achieve sustainable development and increase profitability[151]. - The company is focusing on developing vaccines for African swine fever, having submitted an emergency evaluation application for a subunit vaccine to the Ministry of Agriculture and Rural Affairs[152]. Market and Competition - The company reported a significant decline in revenue due to increased market competition and challenges from the African swine fever prevention environment[43]. - The company aims to enhance its international presence and transition from a production-oriented enterprise to an independent R&D innovation enterprise, increasing investment in R&D platforms[151]. - The overall market for animal vaccines is expected to grow due to the implementation of health farming policies and the demand for vaccine alternatives to pharmaceuticals[177]. - The company plans to enhance its marketing capabilities by developing differentiated epidemic prevention solutions based on customer needs, supported by a robust R&D and production collaboration[180]. Governance and Compliance - The company emphasizes strict compliance with corporate governance and information disclosure regulations to protect shareholder interests[156]. - The company has not experienced any incidents of insider information leakage or insider trading during the reporting period[158]. - The company has established a new independent board member, enhancing its governance structure[171]. - The company’s governance structure includes a clear decision-making process for the remuneration of directors and senior management[193]. Strategic Initiatives - The company has implemented a flexible business strategy to enhance customer engagement and improve market share amid increasing competition[84]. - The company aims to achieve full coverage of large-scale breeding farms by the end of 2022, as per the national guidelines for animal disease prevention[82]. - The company is preparing for market opportunities arising from the "first vaccination, then compensation" policy, enhancing its operational efficiency across various departments[180]. - The company has established a strategy to mitigate the negative impact of the pig cycle on its revenue structure[152]. Dividend and Financial Reporting - The company plans to distribute a cash dividend of 0.60 yuan (including tax) for every 10 shares to all shareholders[18]. - The company has received a standard unqualified audit report from the accounting firm[4]. - The company’s financial report is signed and sealed by the legal representative and accounting personnel, ensuring its authenticity and completeness[21]. - The company’s stock is listed on the Shanghai Stock Exchange, with relevant disclosures made in major financial newspapers[25].

Financial Performance - The company's operating revenue for Q1 2023 was ¥364,004,443.89, representing a year-on-year increase of 6.54%[6] - The net profit attributable to shareholders of the listed company reached ¥106,706,586.04, marking a significant increase of 31.78% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥100,682,016.48, which is an increase of 12.21% year-on-year[6] - The basic earnings per share (EPS) for the period was ¥0.10, reflecting a 42.86% increase from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 364,004,443.89, an increase of 6.9% compared to RMB 341,659,620.42 in Q1 2022[31] - Net profit for Q1 2023 was 110,273,815.05 CNY, compared to 84,009,707.02 CNY in Q1 2022, marking an increase of about 31.2%[39] - Operating profit for Q1 2023 was 128,927,647.11 CNY, up from 106,180,710.00 CNY in Q1 2022, reflecting a growth of approximately 21.4%[39] - Basic earnings per share for Q1 2023 was 0.10 CNY, compared to 0.07 CNY in Q1 2022, indicating a rise of about 42.9%[40] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,456,276,099.18, up 1.05% from the end of the previous year[9] - The total liabilities decreased from RMB 1,039,679,567.09 at the end of 2022 to RMB 996,053,736.04 as of March 31, 2023[29] - The total equity increased from RMB 5,349,655,458.46 at the end of 2022 to RMB 5,460,222,363.14 as of March 31, 2023, indicating a growth of approximately 2.07%[29] - Cash and cash equivalents as of March 31, 2023, were RMB 1,394,807,832.70, slightly down from RMB 1,405,436,474.64 at the end of 2022[23] - The company reported a decrease in accounts payable from RMB 341,489,510.33 in Q4 2022 to RMB 354,818,061.02 in Q1 2023[31] - Accounts receivable increased to 845,801,531.54 CNY from 763,264,979.01 CNY, representing a growth of approximately 10.8%[40] - Inventory rose to 345,744,521.37 CNY from 333,456,874.44 CNY, indicating an increase of about 3.9%[40] Cash Flow - The net cash flow from operating activities was negative at -¥35,342,581.58, indicating a significant change[6] - Cash flow from operating activities in Q1 2023 was 287,890,157.06 CNY, an increase from 252,269,456.51 CNY in Q1 2022, showing a growth of approximately 14.1%[42] - The net cash flow from operating activities was -$35.34 million, compared to -$21.64 million in the previous period, indicating a decline in operational performance[44] - Total cash outflow from operating activities reached $323.23 million, up from $273.90 million year-over-year[44] - Cash inflow from investment activities was $52.48 million, down from $121.04 million in the previous period, reflecting reduced investment returns[44] - The net cash flow from investment activities was $8.44 million, a significant decrease from $76.68 million in the prior year[44] - Cash outflow from financing activities totaled $10.22 million, compared to an inflow of $9.96 million in the previous period, indicating a shift in financing strategy[44] - The ending cash and cash equivalents balance was $1.23 billion, slightly down from $1.25 billion at the end of the previous period[44] Expenses and Subsidies - The company received government subsidies amounting to ¥7,414,301.18, which are closely related to its normal business operations[9] - Total operating costs for Q1 2023 were RMB 236,832,424.14, up from RMB 227,370,832.85 in Q1 2022, reflecting a year-over-year increase of 2%[31] - Research and development expenses for Q1 2023 were RMB 25,934,361.97, slightly down from RMB 26,801,196.11 in Q1 2022[31] - The company paid $43.75 million in various taxes, an increase from $30.02 million in the prior year[44] - Cash paid for other operating activities was $79.11 million, down from $87.54 million, suggesting improved cost management[44] Other Financial Metrics - The weighted average return on equity (ROE) increased by 0.56 percentage points to 2.08%[6] - The company reported a non-recurring loss from the disposal of non-current assets amounting to -¥173,339.84[9] - The company experienced a foreign exchange impact of $137,157.59 on cash and cash equivalents[44] - The company did not adopt new accounting standards for the current reporting period[47]

Financial Performance - The company's operating revenue for Q3 2022 was ¥466,544,863.81, representing a decrease of 6.31% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥105,129,320.08, down 34.57% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥103,095,223.20, a decrease of 24.44% compared to the same period last year[7]. - The basic earnings per share for Q3 2022 was ¥0.09, reflecting a decline of 35.71% year-on-year[10]. - Total operating revenue for the first three quarters of 2022 was ¥1,108,395,348.19, a decrease of 17.1% compared to ¥1,338,392,261.25 in the same period of 2021[32]. - Net profit for the first three quarters of 2022 was ¥204,573,959.84, a decline of 52.0% compared to ¥426,067,383.40 in the same period of 2021[36]. - Operating profit for the first three quarters of 2022 was ¥250,258,672.09, down 44.9% from ¥454,162,708.71 in the previous year[36]. - Total comprehensive income attributable to the parent company was CNY 210,277,260.15, a decrease from CNY 418,898,934.30 in the same period last year, representing a decline of approximately 49.9%[39]. - Basic and diluted earnings per share were both CNY 0.19, down from CNY 0.37 year-over-year, indicating a decrease of about 48.6%[39]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,446,660,040.53, a decrease of 2.38% from the end of the previous year[10]. - The equity attributable to shareholders at the end of the reporting period was ¥5,117,706,899.87, down 2.93% from the previous year[10]. - The total liabilities as of the reporting date were ¥1,046,386,256.26, slightly up from ¥1,043,692,738.64 in the previous year[29]. - The total assets as of the reporting date were ¥6,446,660,040.53, down from ¥6,603,925,651.78 in the previous year[29]. - The company's long-term equity investments decreased marginally to CNY 267.09 million from CNY 268.30 million, a reduction of approximately 0.5%[28]. - The total non-current assets decreased to CNY 3.75 billion from CNY 3.84 billion, indicating a decline of approximately 2.6%[28]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥210,769,176.09, showing a decrease of 18.23% compared to the same period last year[10]. - Net cash flow from operating activities was CNY 210,769,176.09, compared to CNY 257,770,973.41 in the previous year, reflecting a decline of approximately 18.2%[43]. - Cash inflow from operating activities totaled CNY 1,073,033,993.90, down from CNY 1,194,933,674.77, a decrease of about 10.1%[43]. - Cash outflow from operating activities was CNY 862,264,817.81, compared to CNY 937,162,701.36 in the previous year, showing a reduction of approximately 8.0%[43]. - Cash and cash equivalents at the end of the period were CNY 1,063,389,917.23, down from CNY 1,440,193,503.87, indicating a decrease of about 26.1%[45]. - The net cash flow from financing activities was negative at CNY -384,361,603.46, worsening from CNY -118,868,998.30 in the same period last year[45]. Shareholder Information - The company had a total of 74,093 common shareholders at the end of the reporting period[19]. - The company repurchased a total of 27,592,600 shares, which is 2.46% of the total share capital, as part of its stock buyback program[24]. Expenses - Research and development expenses for the first three quarters of 2022 were ¥88,520,367.44, a decrease of 8.5% compared to ¥96,347,351.37 in the same period of 2021[32]. - Sales expenses for the first three quarters of 2022 were ¥193,091,936.40, down 20.9% from ¥243,820,615.42 in the previous year[32]. Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.06%, a decrease of 1.03 percentage points year-on-year[10]. - The company reported a decrease in government subsidies, which contributed to the decline in net profit[15]. - The company's cash and cash equivalents decreased to CNY 1.19 billion from CNY 1.33 billion, representing a decline of approximately 10.5% year-over-year[25]. - The total current assets as of September 30, 2022, were CNY 2.69 billion, down from CNY 2.76 billion, indicating a decrease of about 2.6%[25]. - Accounts receivable increased to CNY 790.96 million from CNY 729.09 million, showing a growth of approximately 8.5% year-over-year[25]. - Inventory levels decreased slightly to CNY 301.61 million from CNY 317.65 million, reflecting a decline of about 5.0%[25]. - The company reported a significant increase in other receivables, rising to CNY 54.55 million from CNY 37.83 million, which is an increase of about 44.2%[25]. - Deferred income tax liabilities were ¥10,198,038.39, a slight decrease from ¥10,482,135.25 in the previous year[29]. - The company paid CNY 123,714,325.23 in dividends and interest, slightly down from CNY 131,430,921.43 year-over-year[43].

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a 15% increase compared to the same period last year[15]. - The net profit attributable to shareholders reached 100 million CNY, showing a growth of 20% year-on-year[15]. - The company's operating revenue for the first half of the year was ¥641,850,484.38, representing a decrease of 23.63% compared to the same period last year[21]. - Net profit attributable to shareholders was ¥104,942,906.60, down 59.32% year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥108,102,309.94, a decrease of 57.02% compared to the previous year[21]. - The basic earnings per share for the period was ¥0.09, down 60.87% from ¥0.23 in the same period last year[21]. - The diluted earnings per share also stood at ¥0.09, showing a 60.87% decrease compared to the previous year[21]. - The total comprehensive income for the period amounted to CNY 258,150,823.52, reflecting a positive performance compared to the previous period[161]. Market and Product Development - User data indicates an increase in active customers by 30%, totaling 1 million users by the end of June 2022[15]. - The company plans to launch two new vaccine products in Q3 2022, aiming to capture a 10% market share in the animal health sector[15]. - Future guidance estimates a revenue growth of 25% for the full year 2022, driven by new product launches and market expansion[15]. - The company focuses on the development of animal vaccines, maintaining a leading market share in foot-and-mouth disease vaccines, with a steady increase in sales revenue from non-foot-and-mouth disease vaccines[29]. - The company is advancing the development of multi-valent vaccines to address customer needs and establish competitive barriers in the market[45]. Research and Development - Research and development expenses increased by 10% to 50 million CNY, focusing on innovative vaccine technologies[15]. - The company's R&D investment reached 76.75 million yuan, accounting for 11.96% of operating revenue, focusing on the development of African swine fever vaccines and other innovative products[45]. - The company established an integrated R&D platform for African swine fever vaccines, with multiple technical pathways progressing steadily, including single, double, and multi-gene deletion vaccines[45]. - The company received 2 invention patents and had 11 invention patent applications accepted during the reporting period, indicating a strong focus on innovation[48]. Financial Position and Cash Flow - The company has maintained a strong cash position with 200 million CNY in cash reserves, ensuring liquidity for upcoming projects[15]. - The net cash flow from operating activities was ¥40,003,276.03, reflecting a decline of 50.02% year-on-year[21]. - The total cash and cash equivalents decreased from ¥1,334,156,187.45 to ¥1,183,775,261.83, representing a decline of approximately 11.3%[123]. - The company reported cash inflows from investment activities totaling CNY 165,329.12 million, compared to CNY 391,528.60 million in the previous year, a decrease of 57.8%[145]. Environmental Compliance and Sustainability - The company has implemented measures to ensure compliance with environmental standards, including the collection and treatment of waste gas[77]. - The wastewater treatment station at Jin Yu Bao Ling has a design capacity of 1,000 m³/d, utilizing a "pulse anaerobic + MBR aerobic" treatment process[82]. - Jin Yu Bao Ling invested CNY 92.34 million in environmental protection measures during the construction of its biotechnology industrial park[80]. - The company achieved zero environmental accidents and received no administrative penalties from higher authorities during the reporting period[90]. Corporate Governance and Management - The company held its 11th Board of Directors and Supervisory Board elections on May 31, 2022, with Zhang Chongyu elected as Chairman and Zhang Jing as Vice Chairman and President[68]. - The company has appointed Li Rong as Vice President during the recent management changes[68]. - The company has seen a complete turnover in its supervisory board, with all members being newly elected[68]. Shareholder Information - The company repurchased a total of 19,782,600 shares, representing 1.76% of the total share capital, through centralized bidding transactions as of June 30, 2022[108]. - The total number of shares increased from 1,126,202,241 to 1,126,202,241 after the share repurchase, with limited sale condition shares rising to 25,615,615[107]. - The number of shareholders reached 77,279 by the end of the reporting period[112].

Financial Performance - The company's operating revenue for Q1 2022 was ¥341,659,620.42, representing a decrease of 34.22% compared to the same period last year[6] - The net profit attributable to shareholders of the listed company was ¥80,972,815.44, down 61.68% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥89,728,564.90, a decrease of 56.73% compared to the previous year[6] - Basic earnings per share were ¥0.07, down 63.16% from the same period last year[6] - Total operating revenue for Q1 2022 was $341.66 million, a decrease of 34.2% compared to $519.42 million in Q1 2021[34] - Net profit for Q1 2022 was $84.01 million, a decline of 61.4% from $217.20 million in Q1 2021[36] - Earnings per share for Q1 2022 were $0.07, compared to $0.19 in Q1 2021[36] Cash Flow - The net cash flow from operating activities was -¥21,635,444.45, reflecting a decline of 179.93% year-on-year[6] - Cash inflow from operating activities for Q1 2022 was $252.27 million, down 30% from $360.86 million in Q1 2021[40] - Net cash outflow from operating activities was -$21.64 million, compared to a positive cash flow of $27.07 million in the same period last year[40] - Cash inflow from investment activities totaled $121.04 million, significantly up from $71.89 million in Q1 2021[41] - Net cash flow from investment activities was $76.68 million, a turnaround from a net outflow of -$111.40 million in Q1 2021[41] - Cash inflow from financing activities was $10 million, with net cash flow from financing activities at $9.96 million[42] - The ending cash and cash equivalents balance for Q1 2022 was $1.25 billion, an increase from $1.24 billion at the end of Q1 2021[42] - The company reported a cash inflow of $20 million from investment recoveries[41] - The company’s cash and cash equivalents increased by $65 million in Q1 2022, contrasting with a decrease of $84.31 million in Q1 2021[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,716,016,378.95, an increase of 1.70% from the end of the previous year[9] - The equity attributable to shareholders of the listed company was ¥5,353,343,185.78, up 1.54% compared to the end of the previous year[9] - Total liabilities increased to $1.07 billion in the latest report from $1.04 billion previously, reflecting a growth of 2.9%[30] - The company’s total liabilities included short-term borrowings of CNY 10,000,000.00, with accounts payable increasing to CNY 386,935,839.24 from CNY 341,808,778.76, a rise of approximately 13.2%[28] - The company’s non-current assets totaled CNY 3,787,249,606.27, down from CNY 3,843,285,602.38, indicating a decrease of about 1.5%[28] Operational Highlights - The decline in operating revenue was primarily due to significant losses in the pig farming industry and a decrease in the number of breeding sows[12] - The company reported non-recurring gains and losses amounting to -¥8,062,981.85, impacting overall profitability[9] - The company’s inventory stood at CNY 331,923,400.66, compared to CNY 317,652,974.28, marking an increase of about 4.5%[24] - The company’s long-term equity investments were valued at CNY 267,952,528.18, slightly down from CNY 268,301,516.68[28] - The company’s other receivables increased to CNY 72,627,196.78 from CNY 37,834,728.18, reflecting a significant growth of approximately 92%[24] Research and Community Engagement - The company’s subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., received a new veterinary drug registration certificate for a Brucella vaccine, currently advancing product approval processes[21] - The company donated a mobile PCR laboratory valued at CNY 3.06 million and cash donations of CNY 7 million to support epidemic prevention efforts[21]